← Back to Clinical Trials
Recruiting NCT06721260

NCT06721260 Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06721260
Status Recruiting
Phase
Sponsor University of Kansas Medical Center
Condition Bladder Cancer
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2025-01-21
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2025-01-21 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care. The study team found in a previous study that resting energy can be different than what estimates show. Patients with bladder cancer are known to suffer a decline in physical resilience over time. Monitoring patients to understand these changes better could help design future treatments with these vulnerabilities in mind.

Eligibility Criteria

Inclusion Criteria: * Confirmed cancer diagnosis * Scheduled for platinum-based chemotherapy followed by radical cystectomy * Adequate renal and cardiac function for platinum-based chemotherapy Exclusion Criteria: * Prior chemotherapy or radiotherapy for bladder cancer * Severe cardiac, renal, hepatic, respiratory or metabolic diseases * Pregnant or breastfeeding * Uncontrolled conditions that could affect study outcomes

Contact & Investigator

Central Contact

Jill M. Hamilton-Reeves, PhD, RD, CSO

✉ jhamilton-reeves@kumc.edu

📞 913-588-7650

Principal Investigator

Jill M Hamilton-Reeves, PhD, RD, CSO

PRINCIPAL INVESTIGATOR

University of Kansas Medical Center

Frequently Asked Questions

Who can join the NCT06721260 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06721260 currently recruiting?

Yes, NCT06721260 is actively recruiting participants. Contact the research team at jhamilton-reeves@kumc.edu for enrollment information.

Where is the NCT06721260 trial being conducted?

This trial is being conducted at Kansas City, United States, Kansas City, United States.

Who is sponsoring the NCT06721260 clinical trial?

NCT06721260 is sponsored by University of Kansas Medical Center. The principal investigator is Jill M Hamilton-Reeves, PhD, RD, CSO at University of Kansas Medical Center. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology